

**Discussions with leaders:** *JNM* editor-in-chief Johannes Czernin, with Thomas Hope, continues a series of interviews with leaders in nuclear and molecular imaging and therapy with a conversation with John J. Sunderland, PhD, MBA, about advancing  $^{68}\text{Ga}$ -DOTATOC through the FDA. . . . . **Page 477**

**The academic NDA:** Sunderland outlines the story of the  $^{68}\text{Ga}$ -DOTATOC new drug application process, including clinical trials, structured content of the NDA document, and associated first-hand experiences from the University of Iowa. . . . . **Page 480**

**Introduction to radiomics:** Mayerhoefer and colleagues provide an educational overview of standard radiomics workflow, the basic concepts of radiomic feature classes, and common limitations and pitfalls in radiomics studies. . . . . **Page 488**

**Travel after  $^{177}\text{Lu}$ -DOTATATE:** Kendi and colleagues look at challenges to gastroenteropancreatic neuroendocrine tumor patients whose residual radiation after  $^{177}\text{Lu}$ -labeled DOTATATE treatment sets off alarms at U.S. borders and points of entry. . . . . **Page 496**

**PET tracer accuracy in gliomas:** de Zwart and colleagues detail the results of a systematic review and metaanalysis comparing the diagnostic accuracies of different PET tracers in differentiating tumor progression from treatment-related changes in patients with high-grade gliomas. . . . . **Page 498**

**$^{18}\text{F}$ -FET PET in recurrent glioma:** Maurer and colleagues investigate the effectiveness of  $^{18}\text{F}$ -FET PET imaging in differentiating glioma progression from treatment-related changes. . . . . **Page 505**

**$^{89}\text{Zr}$ -Df-IAB22M2C anti-CD8 minibody PET:** Pandit-Taskar and colleagues report on first-in-human studies of the safety of this radiolabeled minibody against CD8+ T cells for imaging of these cells in patients with cancer. . . . . **Page 512**

**$^{177}\text{Lu}$ -PP-F11N for radionuclide therapy:** Rottenburger and colleagues determine, using advanced 3-dimensional dosimetry in a first-in-human study, whether this minigastrin analog with therapeutic properties and a

$\gamma$ -ray component for imaging is a suitable agent for treatment of medullary thyroid carcinoma. . . . . **Page 520**

**$^{18}\text{F}$ - versus  $^{68}\text{Ga}$ -PSMA imaging:** Kuten and colleagues compare the diagnostic accuracy of  $^{18}\text{F}$ -PSMA-1007 with that of  $^{68}\text{Ga}$ -PSMA-11 PET/CT in the same group of patients with newly diagnosed intermediate- or high-risk prostate cancer. . . . . **Page 527**

**Interpretation criteria for  $^{68}\text{Ga}$ -PSMA-11 PET:** Torihara and colleagues compare interreader, intrareader, and intercriteria agreement in 3 recently introduced international criteria for interpretation of  $^{68}\text{Ga}$ -prostate-specific membrane antigen-11 PET data in prostate cancer. . . . . **Page 533**

**PSMA PET/CT and biopsy for LN staging:** Hinsenveld and colleagues determine the diagnostic capabilities of combined prostate-specific membrane antigen PET/CT and sentinel node biopsy in PSMA PET/CT-negative patients for primary lymph node staging in prostate cancer. . . . . **Page 540**

**$^{18}\text{F}$ -DCFPyL PET/CT in prostate cancer:** Song and colleagues present their institutional experience assessing the positivity rate of PET/CT with this prostate-specific membrane antigen-targeting agent in patients with biochemical recurrence of prostate cancer. . . . . **Page 546**

**Imaging AUC in BCR prostate cancer:** Jadvar and members of a multiorganizational workgroup provide a consensus document on the appropriate use of imaging in diagnostic evaluation of patients with biochemical recurrence of prostate cancer after definitive primary treatment. . . . . **Page 552**

**Theranostics targeting FAP:** Watabe and colleagues use  $^{64}\text{Cu}$  and  $^{225}\text{Ac}$ , with long half-lives, to label fibroblast activation protein inhibitors in mice with human pancreatic cancer xenografts to assess the potential of  $\alpha$ -therapy targeting FAP in cancer stroma. . . . . **Page 563**

**Imaging  $\beta$ -cell mass with  $^{11}\text{C}$ (+)-PHNO:** Bini and colleagues describe pancreatic PET imaging parameters with this dopamine D<sub>2</sub> and D<sub>3</sub> receptor agonist to differentiate healthy

controls from individuals with type 1 diabetes mellitus. . . . . **Page 570**

**$^{18}\text{F}$ -Fluorocholine in PHPT:** Cuderman and colleagues compare the efficiency of established conventional scintigraphic imaging modalities with  $^{18}\text{F}$ -fluorocholine PET/CT imaging in preoperative localization of hyperfunctioning parathyroid glands in patients with primary hyperparathyroidism. . . . . **Page 577**

**$^{11}\text{C}$ -Choline PET in hyperparathyroidism:** Liu and colleagues assess the value of  $^{11}\text{C}$ -choline PET in patients with primary hyperparathyroidism and negative or discordant results on  $^{99\text{m}}\text{Tc}$ -sestamibi imaging and neck ultrasound. . . . . **Page 584**

**$^{18}\text{F}$ -FDG inflammation imaging after aortic constriction:** Glasenapp and colleagues determine whether inflammation can be serially imaged with  $^{18}\text{F}$ -FDG PET in early stages of pressure-overload-induced heart failure and compare the time course with functional impairment assessed by cardiac MRI. . . . . **Page 590**

**Prediction of conversion to AD:** Blazhenets and colleagues examine the predictive values of amyloid PET,  $^{18}\text{F}$ -FDG PET, and nonimaging predictors (alone and in combination) for development of Alzheimer dementia in a large population of patients with mild cognitive impairment. . . . . **Page 597**

**TSPO versus P2X7 for neuroinflammation:** Van Weehaeghe and colleagues compare imaging with  $^{18}\text{F}$ -DPA714, a second-generation translocator protein tracer, with  $^{11}\text{C}$ -JNJ717, a novel P2X7 receptor tracer, in vitro and in vivo in amyotrophic lateral sclerosis. . . . . **Page 604**

**Dose-response in  $^{166}\text{Ho}$  radioembolization:** Bastiaannet and colleagues investigate the absorbed dose-response relationship and its association with overall survival for  $^{166}\text{Ho}$ -microsphere radioembolization in patients with liver metastases. . . . . **Page 608**

**Oral administration of  $^{18}\text{F}$ -FDG:** Srinivasan and colleagues compare human biodistribution and dosimetry for  $^{18}\text{F}$ -FDG after sequential oral and intravenous administrations in the same subjects to determine dosimetry and potential suitability of oral  $^{18}\text{F}$ -FDG as an alternative to intravenous administration. . . . . **Page 613**